Cells possessing glucagon-and glucagon-like immunoreactivity (GLI) were studied by an indirect immunofluorescence technique in the normal canine gastrointestinal mucosa and pancreas. Glucagon-immunoreactivity was demonstrated in the basal-granulated cells in the deeper portion of the fundic gland of the stomach as well as in the A cells of the pancreatic islet.
Summary.
Cells possessing glucagon-and glucagon-like immunoreactivity (GLI) were studied by an indirect immunofluorescence technique in the normal canine gastrointestinal mucosa and pancreas. Glucagon-immunoreactivity was demonstrated in the basal-granulated cells in the deeper portion of the fundic gland of the stomach as well as in the A cells of the pancreatic islet.
GLI-positive basal-granulated cells were found in the fundus of the stomach, jejunum, ileum and colon. None of them were found in the pyloric antrum and duodenum. Careful examination of the immunofluorescence specimens gave us the impression that essentially every GLI-positive cell in the gastric fundus and pancreas contained glucagon. It was observed that the GLI-positive cells in the jejunum, ileum and colon were open in type reaching the lumen with their tapered luminal process, whereas the glucagon/GLIpositive cells in the stomach were always separated from the lumen by a layer of other epithelial cells so that they were closed in type.
The possible difference in the way of stimulus-reception between the GLI-positive cells in the intestine and glucagon/GLI-positive cells in the stomach was discussed with particular reference to the idea that basal-granulated cells could receive information for their secretory activity not only from the gut lumen but also from the blood side.
In 1949, SUTHERLAND and DE DUVE demonstrated that the extracts of the dog gastro-intestinal tissues had the glucagon-like hyper-glycemic-glycogenolytic activity. UNGER and his co-workers (1961) confirmed the original observations of SUTHER-LAND and DE DUVE by the technique of radioimmunoassay and named the material cross-reactive to the anti-glucagon serum glucagon-like immunoreactivity (GLI, UNGER, et al., 1968) . Since then, it has been a matter of dispute whether the material with GLI contains glucagon. Recent radio-immunoassay studies using a specific antiserum to glucagon by VRANIC, PEK and KAWAMORI (1974) and MATSUYAMA and FOA (1974) demonstrated hyperglucagonemia occurring in depancreatized dogs untreated with insulin. MASHITER and his co-workers (1975) revealed that plasma glucagon level in depancreatized dogs rose in response to intravenous infusion of L-arginine and that plasma glucagon level in the portal vein was higher than that in the femoral artery.
Furthermore, SASAKI and his co-workers (1975) found in the porcine gastrointestinal extracts a component that was indistinguishable from pancreatic glucagon by immunological and biological methods.
All these findings suggest that glucagon exists in the extra-pancreatic tissues, particularly in the gastro-intestinal tract. As to the cellular origin of GLI, POLAK and her co-workers (1971) reported on the basis of the results of their immunofluorescence studies that GLI-positive cells existed in the gastric fundus, jejunum, ileum and colon in the dog. However, since they did not distinguish GLI-cross-reactive antisera from glucagon-specific antisera, it remained obscure whether their GLI-positive cells possessed glucagon.
In an attempt to 193 solve this problem, LARSSON and his co-workers (1975) examined the gut and pancreas of the pig, cat, dog and rat using two different kinds of anti-glucagon antisera, i.e., glucagon-specific antisera and GLI-cross-reactive antisera. They found cells reacting to both of the two kinds of anti-glucagon antisera (glucagon/GLI-positive cells) in the fundus of the stomach. On the other hand, cells reacting only to GLI-crossreactive antisera (GLI-positive cells) were found in the duodenum, jejunum, ileum and colon.
The first purpose of the present study was to ascertain the observations of LARSSON and his co-workers (1975) on the occurrence of the glucagon/GLI-and GLIpositive cells in the canine gut and pancreas, by the use of the glucagon-specific and GLI-cross-reactive antisera prepared in our laboratory (ITO, SUZUKI and SASAKI, 1975) . The second purpose of the study was to examine the morphological differences between the glucagon/GLI-positive cells in the stomach and GLI-positive cells in the intestine, and to discuss the functional significance of these differences.
Materials and Methods

Anti-glucagon antisera
Preparation of glucagon-specific antisera. ASSAN and SLUSHER (1972) showed that glucagon has two antigenic sites inside the molecule. One is located at the C-terminal and the other at the N-terminal and central portions of the molecule. Since it was demonstrated that glutaraldehyde bridges free amino groups of different protein molecules (RICHARDS and KNOWLES, 1968) , it might be assumed that glutaraldehyde modifies lysine moieties in the N-terminal and central portions of glucagon and destroys the antigenicity located at these portions of the molecule which are the sites most often bound by GLI-cross-reactive antisera (ASSAN and SLUSHER, 1972) .
In the present study, we prepared antisera specific to the C-terminal portion of glucagon molecule which lacks free amino groups by following procedures: (1) Crystalline glucagon (12mg, Sigma) dissolved in 0.3ml of 0.02N hydrochloric acid was added to a mixture of 1ml of NN-dimethyl-formamide and 0.7ml of 0.1M phosphate buffer of pH 7.4 containing 4mg of bovine serum albumin (BSA, Sigma). (2) Glutaraldehyde (0.5% aqueous solution, 0.05ml) was added to this mixture and allowed to stand for 2hrs at room temperature. (3) Then, this glucagon-glutaraldehyde-BSA mixture was dialized for 24hrs against 1l of 0.1M potassium phosphate buffer of pH 7.4. (5) The dialized material was emulsified with an equal amount of complete Freund Adjuvant (Difco). (6) A subcutaneous injection of glucagon-glutaraldehyde-BSA conjugate was performed once a month for 5 months in 4 healthy adult rabbits (G-1, G-5, G-7 and G-8). Two weeks after the final booster, about 1 dl of blood was collected from each rabbit and the blood serum containing anti-glucagon antibodies was prepared according to a routine method.
Preparation of GLI-cross-reactive antisera. As mentioned above the anti-glucagon antisera prepared by the glutaraldehyde method most probably react to the C-terminal portion of glucagon and mask the antigenicity of this portion of the molecule.
In order to prepare antisera specific for both the N-terminal and central portions of glucagon, a glucagon-anti-glucagon antibody complex prepared by incubating 2mg of glucagon, 5000 units of Trasylol (Bayer) and 2ml of the anti-glucagon anti-AE-3). Fourty days after the first injection, glucagon emulsified with 2ml of Freund Adjuvant was injected into the animals, in place of the glucagon-anti-glucagon antibody complex which was used in the first injection. Two weeks after the fifth injection of the glucagon-Freund Adjuvant complex, sera containing GLI-cross-reactive antibodies were prepared.
GLI-extracts. The GLI-extracts used in the present study were prepared by the method described by KENNY (1955) .
Specificity of the anti-glucagon antisera. Firstly, the sensitivity of anti-glucagon antisera produced by the two methods described above was examined by radioimmunoassay. Glucagon-specific antisera and GLI-cross-reactive antisera obtained from the rabbits, G-8 and AE-1 respectively, were the most sensitive among the samples examined.
These two antisera then were used throughout this study after the examination of the cross-reactivity to the GLI-extracts using a dilution slope of radioimmunoassay (Table 1) .
Immunofluorescence histochemistry
Pieces of the gastro-intestinal tract and pancreas obtained from adult, male mongrel dogs were fixed in Bouin's fluid for 2hrs at room temperature and dehydrated glass slides coated with a mixture of 0.5% gelatin and 0.05% chromium potassium sulfate. Sections deparaffinized in xylene were treated with either the glucagon-specific antisera obtained from the G-8 rabbit or GLI-cross-reactive antisera obtained from the AE-1 rabbit in the final dilution of 1/15 in 0.01M phosphate buffered physiological
Control study
In order to examine the specificity of the reaction between the glucagon-specific and GLI-cross-reactive antisera used in the present study and the tissue glucagon and Table 1 . The cross-reactivity of two anti-glucagon antisera used in the present study to GLI extracts (ITO, SUZUKI and SASAKI, 1975) The values for G-8 and AE-1 antisera are calculated on the basis of dilution curve of radioimmunoassay for glucagon.
GLI, following control studies were carried out: (1) Sections were incubated with one of the two kinds of anti-glucagon antisera pre-treated with an excess amount of glucagon. Then, the sections were allowed to react with anti-rabbit IgG-FITC.
(2) Sections were treated with normal rabbit serum followed by incubation with antirabbit IgG-FITC.
(3) Sections were incubated with either one of the two kinds of glucagon antisera or anti-rabbit IgG-FITC alone, and then, examined in the fluorescence microscope.
Results
Cells reacting to the glucagon-specific antisera
In the pancreas, cells reacting to the glucagon-specific antisera were found mainly in the periphery of the islet (Fig. 1) . They also occurred in the extra-islet tissues. Their distribution seemed to coincide with that of A-cells examined by conventional histological methods.
In the stomach, specific immunofluorescence was found in the basal-granulated cells in the deeper portion of the fundic gland. These cells were oval in shape and did not reach the lumen of the gland (Fig. 3) .
Glucagon-positive basal-granulated cells were not demonstrated in other portions of the gut examined, i.e., the duodenum, jejunum, ileum and colon.
Cells reacting to the GLI-cross-reactive antisera
In the pancreas, immunofluorescence for the GLI-cross-reactive antisera was frequently seen in the cells located in the marginal portion of the islet. A few GLI- positive cells were also seen in the extra-islet tissues. Distribution and number of these cells corresponded to that of glucagon-positive cells in the pancreas mentioned above (compare Fig. 1 and Fig. 2) .
In the stomach, GLI-positive cells were found only in the fundus. The majority of them were located in the base of the fundic gland. A small number of them were also seen among other epithelial cells in the neck of the gland. They appeared to be oval in shape and did not reach the lumen of the gland (Fig. 4) . By a careful examination of the specimen, the GLI-positive cells in the stomach coinsided in their distribution and morphology to the glucagon-positive cells mentioned above. Thus, it seemed probable that a single type basal-granulated cells reacted to both glucagonspecific and GLI-cross-reactive antisera.
In the jejunum, ileum and colon, GLI-positive basal-granulated cells occurred mainly in the deeper portion of the crypt. Population density of them was decreased in the order of the ileum, jejunum and colon. They clearly reached the cryptal lumen with their tapered cytoplasmic process (Fig. 5-7 ).
Control study
As the immunofluorescence was not found in the sections used in the control studies, the specificity of the reaction between the glucagon-specific and GLI-crossreactive antisera used in the present study and tissue glucagon and GLI was confirmed.
Discussion
In the present study, we demonstrated basal-granulated cells reacting to both glucagon-specific and GLI-cross-reactive antisera in the fundus of the canine stomach. These cells are identical with the pancreatic A cells at least from the immunohistochemical point of view. On the other hand, in the intestine we found only GLIpositive cells. Thus, our results confirmed the description of LARSSON and his coworkers (1975) who claimed that glucagon/GLI-positive cells existed in the canine fundic gland and that GLI-positive cells in the intestine were devoid of glucagon.
According to FUJITA and KOBAYASHI (1973) , the open type basal-granulated cells are able to receive adequate chemical stimuli in the gut lumen with their apical process, while closed type of them cannot (see, Fig. 8) . Thus, the GLI-positive cells in the intestine would be able to recognize the luminal chemical stimuli, whereas the glucagon/GLI-positive cells in the stomach would not, the latter being separated from the lumen by a layer of other epithelial cells.
UNGER and his co-workers (1968) reported that the intraduodenal administration of glucose in the dog stimulated the secretion of GLI from the gut, however, the intravenous injection did not. It was also reported that an oral glucose load in the normal persons elevated the plasma GLI level, although no change or even a drop was found in the level of glucagon (HEDING, 1968 (HEDING, , 1971 . In gastrectomized patients as compared with healthy subjects, the increase of plasma GLI after oral administration of glucose is conspicuous (SHIMA et al., 1972) . All these data reported by the previous authors might well be accounted for by the present observations that GLIpositive basal-granulated cells in the intestine contain no glucagon and are open in type. FUJITA and KOBAYASHI (1973) have postulated that the secretion of hormones of the closed type basal-granulated cells could be caused by the physical stimuli in the gut lumen such as the distension of the cells accompanying the uptake of foodstuff. It might be assumed that glucagon released from the glucagon/GLI-positive cells in the fundic mucosa by a mechanical effect of meal could, passing through the liver, increase glycogenolysis in the liver cells and further, after entering the general circulation, enhance insulin release from the pancreatic islets.
According to FUJITA and KOBAYASHI (1973) (Fig. 8) , both open and closed types of basal-granulated cells can receive information for their secretory activity from the blood front in addition to the luminal surface, although the kinds of blood born adequate stimuli should be different from cell type to cell type as in the case of the luminal stimuli.
Raised plasma glucose levels remarkably inhibit the release of glucagon (OHNEDA et al. 1969) , while their influence on the plasma GLI-levels is indistinct (UNGER et al., 1968) . This is consistent with the idea that the GLI-positive cells in the intestine, MASHITER and his co-workers (1975) demonstrated a remarkable increase in the plasma level of the reactivity to the glucagon-specific antisera in the depancreatized dog after an intravenous injection of L-arginine.
It seems probable that the release of glucagon took place from the glucagon/GLI-positive cells in the stomach of these animals, because they had no pancreatic islets.
The result of the experiment of MASHITER and his co-workers (1975) in the depancreatized dog favors the view that the closed type basal-granulated cells can release hormones in response to the blood born stimuli.
In our previous study (ITO, SUZUKI and SASAKI, 1975) , we failed to demonstrate glucagon-positive cells in the canine gut fixed in one of the following three kinds of fixatives: 2% carbodiimide solution, a mixture of 1% glutaraldehyde and 2% paraformaldehyde and 95% ethanol. The present positive result and previous negative one in the demonstration of glucagon-positive cells in the canine gut seems to be due to the different effect of the fixatives used on the preservation of the antigenicity of tissue glucagon.
